Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD

Stephen Hanauer, MD, Joshua Korzenik, MD, and Florian Rieder, MD join the board BRANFORD, CT – (GlobeNewswire – December 11, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel disease (IBD), announced that Stephen Hanauer, MD, Josh Korzenik, MD, and Florian Rieder, MD, have joined Thetis’ Scientific […]

Senator Chris Murphy Names Thetis Connecticut Innovator of the Month

WASHINGTON – In recognition of Crohn’s and Colitis Awareness Week, U.S. Senator Chris Murphy (D-Conn.) announced on Tuesday that Branford’s Thetis Pharmaceuticals – a biopharmaceutical company developing new oral therapies to treat inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis – is this month’s “Murphy’s Innovator of the Month.” Thetis has a proprietary HEALER™ […]

Immuno-resolution: The Next Frontier for Treating Inflammatory Diseases

Uncontrolled inflammation is an important component of many chronic diseases, including arthritis, asthma, psoriasis, arteriosclerosis, and inflammatory bowel disease (IBD). Treatment of these diseases often utilizes anti-inflammatory agents that block steps in the inflammatory response and suppress the immune system. Unfortunately, such agents are only partially effective and can lead to undesirable side effects such […]

Thetis Receives $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease

Resolvin-based agent targets inflammation resolution and tissue regeneration without immunosuppression BRANFORD, CT – (GlobeNewswire – November 16, 2017) – Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). The […]